{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-23-003664","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.898775+00:00","generated_at":"2026-06-08T03:40:33.215295+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Entera Bio reports Q3 net loss $2.4M; advances oral peptide pipeline with OPKO collaboration, Phase 3-ready EB613","bullets":["Net loss $2.4M ($0.08/share) vs $3.1M ($0.11) in Q3 2022; cash $7.6M sufficient into Q3 2024.","FDA concurred that 2-year Phase 3 study with BMD endpoint could support NDA for EB613 (oral PTH) in osteoporosis.","Collaboration with OPKO to develop oral GLP-2 for short bowel syndrome and oxyntomodulin for obesity; updates expected H1 2024.","EB612 (oral PTH for hypoparathyroidism) Phase 2a met endpoints; ongoing PK/PD study results expected end of 2023.","Operating expenses $2.4M, down from $2.9M YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-23-003664","json":"https://secwatch.observer/filing/0001178913-23-003664.json","markdown":"https://secwatch.observer/filing/0001178913-23-003664.md","text":"https://secwatch.observer/filing/0001178913-23-003664.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891323003664/0001178913-23-003664-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891323003664/zk2330537.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:40:33.215295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5d281bcefad715367d972d863ceeefd464f0d802","claim":"Entera Bio Ltd. reported financial results for the third quarter ended September 30th, 2023.","evidence_excerpt":"On November 14, 2023, Entera Bio Ltd., a company organized under the laws of the State of Israel (“we,” “us,” “our” or the “Company”), issued a press release announcing its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638097/000117891323003664/0001178913-23-003664-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30th, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}